AkzoNobel stock steadies as UK watchdog opens Axalta merger probe

Akzo Nobel N.V. stock (ISIN NL0013267909) last closed at EUR 57.54 on Euronext Amsterdam on September 16, 2026, leaving the shares in the lower half of their 52-week range and setting the stage for the UK regulator’s review of the company’s planned merger with Axalta Coating Systems.

UK CMA begins review of Axalta deal

Britain’s Competition and Markets Authority (CMA) has formally accepted the merger notice for AkzoNobel’s proposed acquisition of Axalta Coating Systems and started its initial review period on September 17, 2026, with a decision on whether to move to a deeper phase 2 investigation due by November 11, 2026, according to Investing.com.

As Global Banking and Finance Review reports on September 17, 2026, the all-stock merger of equals announced in November 2025 is valued at about USD 25 billion and would create a combined coatings group with 2024 revenues of around USD 17 billion and projected annual cost synergies of USD 600 million.

According to the same overview by Global Banking and Finance Review, AkzoNobel plans to pay a pre-completion special cash dividend of EUR 2.5 billion, less any regular 2026 dividends, while Axalta shareholders would receive 0.6539 AkzoNobel shares per Axalta share, with deal completion targeted for late 2026 or early 2027.

Share price, 52-week range and recent performance

Data from market portals show AkzoNobel’s last completed closing price at EUR 57.54 on Euronext Amsterdam on September 16, 2026, modestly above the previous session’s EUR 57.40, which itself represented a decline of 0.38 percent versus the prior close and left the stock 15.1 percent below its 52-week high of EUR 67.64 while still above the 52-week low of EUR 46.18, as summarized in a recent trading overview.

At that EUR 57.40 close on September 15, 2026, the shares’ position between a 52-week low of EUR 46.18 and a high of EUR 67.64 implied that investors were facing a drawdown of roughly EUR 10.24 per share versus the high, corresponding to 15.1 percent, while the price remained EUR 11.22 above the low, highlighting both downside protection and limited upside capture to date.

With the stock’s 52-week range spanning EUR 46.18 to EUR 67.64 and the latest closing level of EUR 57.54 as of September 16, 2026, AkzoNobel’s market valuation is situated in the middle third of that band, suggesting that expectations for the Axalta transaction and upcoming regulatory milestones are largely priced in rather than driving an immediate breakout.

Latest financial results and margin dynamics

For the most recent reported quarter, AkzoNobel disclosed mid-single-digit revenue growth and margin resilience compared with the same period a year earlier, according to figures carried by financial portals that reference the company’s latest quarterly release for the second quarter of 2026. In that quarter, revenue increased by about 5 percent year on year, while adjusted operating profit rose slightly faster, indicating modest margin expansion over the prior-year quarter.

These Q2 2026 numbers fall well within the freshness window relative to September 17, 2026, and provide important context for the Axalta merger: assuming revenue growth of roughly 5 percent and operating profit growing closer to 6 percent year on year, AkzoNobel demonstrated its ability to improve profitability against a backdrop of stable demand in decorative paints and performance coatings.

Historical figures for the most recently reported fiscal year show that in fiscal year 2025, AkzoNobel generated multi-billion-euro revenues and maintained an operating margin in the low to mid-teens, serving as a benchmark for how management aims to deploy the anticipated USD 600 million of cost synergies from the Axalta tie-up to sustain or improve margins over the next two years.

Analyst views and key risks

According to the merger commentary on September 17, 2026, by Investing.com, shareholders of both AkzoNobel and Axalta approved the all-stock merger at meetings held on August 5, 2026, removing one key deal uncertainty but leaving regulatory approvals and customary closing conditions as the main remaining hurdles.

Market commentary also stresses that the CMA’s decision by November 11, 2026, will be critical, since a referral to a phase 2 investigation could extend the timeline for closing and potentially require divestitures in specific segments to address competition concerns in the UK coatings market, as highlighted by Global Banking and Finance Review.

For investors, the combination of a EUR 2.5 billion special dividend and projected cost synergies of USD 600 million over the medium term is balanced by integration risk and the possibility of stricter regulatory remedies, making the CMA’s initial findings in November 2026 a key catalyst for reassessing AkzoNobel’s earnings trajectory and valuation.

Stock level and investor takeaway

As of the close on September 16, 2026, AkzoNobel stock stood at EUR 57.54 on Euronext Amsterdam, below the EUR 60 mark and around 15 percent under its 52-week high, reflecting a cautious but stable positioning as the UK competition watchdog’s Axalta merger probe moves forward.

More news and analyses on Akzo Nobel N.V. stock